Special Issue

Photodynamic Therapy 2022

Message from the Guest Editor

Photodynamic therapy (PDT) is a light-based photochemistry process. The illumination of a photoactivatable molecule (also called photosensitizer) with visible or near infrared light produces reactive oxygen toxic species to destroy tumor cells. PDT has proven to be a promising modality in many medical applications, including cutaneous conditions, infectious diseases, and various cancers at different stages. The iournal Pharmaceuticals invites both reviews and original articles shedding light on the challenges and opportunities of the development of innovative solutions for photodynamic therapy. Topics include selective photoactivatable molecules targeting receptors overexpressed into tumor membranes and/or on neovessels; molecules exhibiting red shifted absorption for better penetration of light into tissues; photobactericidal agents; theranostics; and photodiagnosis. Reviews and original articles dealing with PDT-associated immunotherapy, new radiation systems such as X-rays, or new devices allowing for better illumination and/or dosimetry are also welcome.

Guest Editor

Dr. Céline Frochot

LRGP, Laboratoire Réactions et Génie des Procédés, UMR 7274 CNRS-Université de Lorraine, 1 Rue Grandville, 54000 Nancy, France

Deadline for manuscript submissions

closed (31 May 2022)



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/102512

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

